EMMA — Emmaus Life Sciences Balance Sheet
0.000.00%
- $0.70m
- $30.25m
- $16.65m
- 23
- 88
- 25
- 42
Annual balance sheet for Emmaus Life Sciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K/A | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 2.49 | 2.28 | 2.02 | 2.55 | 1.39 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.198 | 1.04 | 0.375 | 5.52 | 2.62 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 11.3 | 9.09 | 6.29 | 11.5 | 6.77 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 4.19 | 3.63 | 2.87 | 2.4 | 1.58 |
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 59.5 | 56.7 | 48.2 | 35.2 | 23.6 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 23.4 | 37.1 | 54.3 | 61.5 | 63.6 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 64.7 | 78.2 | 82.3 | 82.9 | 80.1 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | -5.16 | -21.4 | -34.1 | -47.8 | -56.5 |
| Total Liabilities & Shareholders' Equity | 59.5 | 56.7 | 48.2 | 35.2 | 23.6 |
| Total Common Shares Outstanding |